In this prespecified interim analysis, treatment with atacicept resulted in a significantly greater reduction in proteinuria than placebo at week 36 in patients with IgA nephropathy. (Funded by Vera Therapeutics; ORIGIN 3 ClinicalTrials.gov number, NCT04716231.).

This study compares Early Start Peritoneal Dialysis (ESPD) with Conventional Start Peritoneal Dialysis (CSPD), finding that while ESPD may l